The SARS threat in Israel: one medical center's experience.

J Nurs Adm

Continuing Nursing Education Unit, Tel-Aviv University, Israel.

Published: September 2004

Download full-text PDF

Source
http://dx.doi.org/10.1097/00005110-200407000-00002DOI Listing

Publication Analysis

Top Keywords

sars threat
4
threat israel
4
israel medical
4
medical center's
4
center's experience
4
sars
1
israel
1
medical
1
center's
1
experience
1

Similar Publications

Recent surges in COVID-19 cases demonstrate the unabated transmissibility of this disease. Despite the ongoing threat of contagion, however, uptake of the COVID-19 vaccines, especially as booster doses, remains suboptimal among eligible adults and children in the United States, as reported by the World Health Organization (WHO). Public attitudes toward these vaccines remain balkanized, with some groups harboring ambivalence or even opposition to receiving inoculation.

View Article and Find Full Text PDF

Five years after COVID-19 surfaced, scientists reflect and look ahead to the next threat.

View Article and Find Full Text PDF

Measles, a highly contagious respiratory illness caused by the measles virus (MeV), poses significant global and national public health challenges despite advancements in vaccination efforts. Though measles was declared eliminated in the United States in 2000, recent years have seen a resurgence of cases, particularly in under-vaccinated communities. This resurgence is compounded by factors such as vaccine hesitancy, the impact of the COVID-19 pandemic on immunization rates, and international travel introducing new cases from endemic regions.

View Article and Find Full Text PDF

The dynamics of the genetic diversity of pathogens, including the emergence of lineages with increased fitness, is a foundational concept of disease ecology with key public-health implications. However, the identification of such lineages and estimation of associated fitness remain challenging, and is rarely done outside densely sampled systems. Here we present phylowave, a scalable approach that summarizes changes in population composition in phylogenetic trees, enabling the automatic detection of lineages based on shared fitness and evolutionary relationships.

View Article and Find Full Text PDF

In vitro to clinical efficacy: Neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 strains.

J Infect Chemother

December 2024

Department of Infectious Diseases, Hiroshima University Hospital, 1-2-3 Kasumi, Minamiku, Hiroshima 734-8551, Japan. Electronic address:

Introduction: Neutralizing antibodies have been approved for coronavirus disease 2019 (COVID-19) treatment; however, no study has clarified the link among their neutralizing effect in vitro, the period of infectious virus shedding, and symptoms in the acute phase. Here, we aimed to assess the duration of virus shed and fever in patients with mild COVID-19 stratified by their characteristics and type of neutralizing antibody administered.

Methods: We evaluated the efficacy of neutralizing antibodies in terms of the duration of infectious virus excretion and fever in three groups: patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta strain treated with REGEN-CoV2 (REGN-CoV2 group) and patients infected with Omicron strain treated with S309 (S309 group) or untreated (untreated group).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!